{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:36:14Z","timestamp":1787798174665,"version":"build-2784847793"},"reference-count":239,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravascular thrombus formation and embolization are among the most frequent events leading to a number of cardiovascular conditions with high morbidity and mortality. The underlying causes are stasis of the circulating blood, genetic and acquired coagulation disorders, and reduced antithrombotic or prothrombotic properties of the vascular wall (Virchow\u2019s triad). In the venous system, intravascular thrombi can cause venous thrombosis and pulmonary and even peripheral embolism including ischaemic stroke [through a patent foramen ovale (PFO)]. Thrombi in the left atrium and its appendage or ventricle form in the context of atrial fibrillation and infarction, respectively. Furthermore, thrombi can form on native or prosthetic aortic valves, within the aorta (in particular at sites of ulcers, aortic dissection, and abdominal aneurysms), and in cerebral and peripheral arteries causing stroke and critical limb ischaemia, respectively. Finally, thrombotic occlusion may occur in arteries supplying vital organs such the heart, brain, kidney, and extremities. Thrombus formation and embolization can be managed with anticoagulants and devices depending on where they form and embolize and on patient characteristics. Vitamin K antagonists are preferred in patients with mechanical valves, while novel oral anticoagulants are first choice in most other cardiovascular conditions, in particular venous thromboembolism and atrial fibrillation. As anticoagulants are associated with a risk of bleeding, devices such as occluders of a PFO or the left atrial appendage are preferred in patients with an increased bleeding risk. Platelet inhibitors such as aspirin and\/or P2Y12 antagonists are preferred in the secondary prevention of coronary artery disease, stroke, and peripheral artery disease either alone or in combination depending on the clinical condition. A differential and personalized use of anticoagulants, platelet inhibitors, and devices is recommended and reviewed in this article.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehab642","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:44:26Z","timestamp":1631101466000},"page":"940-958","source":"Crossref","is-referenced-by-count":17,"title":["Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-538X","authenticated-orcid":false,"given":"Thomas F","family":"L\u00fcscher","sequence":"first","affiliation":[{"name":"Royal Brompton & Harefield Hospitals , Heart Division, Guy Scadding Building, Dovehouse Street, Imperial College , London SW3 6LY, UK"},{"name":"Center for Molecular Cardiology, University of Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Davies","sequence":"additional","affiliation":[{"name":"Royal Brompton & Harefield Hospitals , Heart Division, Guy Scadding Building, Dovehouse Street, Imperial College , London SW3 6LY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juerg H","family":"Beer","sequence":"additional","affiliation":[{"name":"Center for Molecular Cardiology, University of Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-7110","authenticated-orcid":false,"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"CardioCentro , Lugano, Switzerland"},{"name":"University of Bern , Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9671-8030","authenticated-orcid":false,"given":"Christoph A","family":"Nienaber","sequence":"additional","affiliation":[{"name":"Royal Brompton & Harefield Hospitals , Heart Division, Guy Scadding Building, Dovehouse Street, Imperial College , London SW3 6LY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Camm","sequence":"additional","affiliation":[{"name":"St. Georges University and Imperial College , London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Angiology, Inselspital Bern , Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-8612","authenticated-orcid":false,"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty of the University Duisburg-Essen , Duisburg-Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-7279","authenticated-orcid":false,"given":"Stavros V","family":"Konstantinides","sequence":"additional","affiliation":[{"name":"Center for Thrombosis and Hemostasis, University Medical Center Mainz , Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"2022102614281373200_ehab642-B1","first-page":"475","article-title":"High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis","volume":"83","author":"Zoller","year":"1996","journal-title":"Thromb Res"},{"key":"2022102614281373200_ehab642-B2","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2015-01-613588","article-title":"Introduction to a series of reviews on inherited bleeding disorders","volume":"125","author":"Lillicrap","year":"2015","journal-title":"Blood"},{"key":"2022102614281373200_ehab642-B3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cjca.2012.10.024","article-title":"Genetics of coagulation: what the cardiologist needs to know","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"key":"2022102614281373200_ehab642-B4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1126\/science.1180660","article-title":"Genotype analysis identifies the cause of the \u201croyal disease\u201d","volume":"326","author":"Rogaev","year":"2009","journal-title":"Science"},{"key":"2022102614281373200_ehab642-B5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor","volume":"67","author":"Sadler","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"2022102614281373200_ehab642-B6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11239-019-01849-2","article-title":"Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians","volume":"48","author":"Mehta","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2022102614281373200_ehab642-B7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.105.567297","article-title":"Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications","volume":"113","author":"Steffel","year":"2006","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B8","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1538-7836.2010.03840.x","article-title":"A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin","volume":"8","author":"Mahmoodi","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2022102614281373200_ehab642-B9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jth.12461","article-title":"Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MAR seilles-NI mes prediction model","volume":"12","author":"Cohen","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2022102614281373200_ehab642-B10","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1001\/jama.293.19.2352","article-title":"Thrombophilia, clinical factors, and recurrent venous thrombotic events","volume":"293","author":"Christiansen","year":"2005","journal-title":"JAMA"},{"key":"2022102614281373200_ehab642-B11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(98)06448-4","article-title":"Association of two silent polymorphisms of platelet glycoprotein Ia\/IIa receptor with risk of myocardial infarction: a case-control study","volume":"353","author":"Moshfegh","year":"1999","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11239-011-0586-5","article-title":"Platelet receptor gain-of-function single nucleotide polymorphisms in carotid and vertebral stenosis patients","volume":"32","author":"Lugli","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"2022102614281373200_ehab642-B13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B14","doi-asserted-by":"crossref","first-page":"e005595","DOI":"10.1161\/CIRCOUTCOMES.118.005595","article-title":"Atrial fibrillation burden signature and near-term prediction of stroke: a machine learning analysis","volume":"12","author":"Han","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022102614281373200_ehab642-B15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/STROKEAHA.120.030663","article-title":"Automated electronic phenotyping of cardioembolic stroke","volume":"52","author":"Guan","year":"2021","journal-title":"Stroke"},{"key":"2022102614281373200_ehab642-B16","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B17","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"Diener","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B18","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1161\/STROKEAHA.119.026512","article-title":"Antithrombotic treatment in cryptogenic stroke patients with patent foramen ovale: systematic review and meta-analysis","volume":"50","author":"Sagris","year":"2019","journal-title":"Stroke"},{"key":"2022102614281373200_ehab642-B19","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1253\/circj.CJ-16-0995","article-title":"Epidemiology of myocardial infarction caused by presumed paradoxical embolism via a patent foramen ovale","volume":"81","author":"Kleber","year":"2017","journal-title":"Circ J"},{"key":"2022102614281373200_ehab642-B20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fneur.2019.00137","article-title":"A case of paradoxical embolism causing anterior spinal cord syndrome and acute myocardial infarction following the intradiscal oxygen-ozone therapy","volume":"10","author":"He","year":"2019","journal-title":"Front Neurol"},{"key":"2022102614281373200_ehab642-B21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-term outcomes of patent foramen ovale closure or medical therapy after stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B22","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis","volume":"65","author":"Holmes","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/eurheartj\/ehy121","article-title":"Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials","volume":"39","author":"Ahmad","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke","volume":"377","author":"S\u00f8ndergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1212\/WNL.0b013e3182a08d59","article-title":"An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke","volume":"81","author":"Kent","year":"2013","journal-title":"Neurology"},{"key":"2022102614281373200_ehab642-B27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jacc.2003.10.030","article-title":"Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients","volume":"43","author":"Krumsdorf","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.0954-6820.1969.tb07351.x","article-title":"Atrial fibrillation. I. A study of atrial thrombosis and systemic embolism in a necropsy material","volume":"185","author":"Aberg","year":"2009","journal-title":"Acta Med Scand"},{"key":"2022102614281373200_ehab642-B30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"2022102614281373200_ehab642-B31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-123-11-199512010-00001","article-title":"Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study","volume":"123","author":"Manning","year":"1995","journal-title":"Ann Intern Med"},{"key":"2022102614281373200_ehab642-B32","first-page":"270","article-title":"Role of transesophageal echocardiography in detecting left atrial thrombus and spontaneous echo contrast in patients with mitral valve disease or non-rheumatic atrial fibrillation","volume":"89","author":"Tsai","year":"1990","journal-title":"J Formos Med Assoc"},{"key":"2022102614281373200_ehab642-B33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0735-1097(94)90025-6","article-title":"Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation","volume":"24","author":"Leung","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B34","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/0735-1097(88)90283-5","article-title":"Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk","volume":"11","author":"Daniel","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B35","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0735-1097(98)00146-6","article-title":"Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators","volume":"31","author":"Zabalgoitia","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"Canadian Atrial Fibrillation Anticoagulation (CAFA) study","volume":"18","author":"Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B37","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"323","author":"Singer","year":"1990","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B38","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B41","doi-asserted-by":"crossref","first-page":"O14","DOI":"10.1093\/eurheartj\/suaa178","article-title":"Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal","volume":"22","author":"Lane","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"2022102614281373200_ehab642-B42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ehjcvp\/pvz016","article-title":"Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke","volume":"5","author":"Sulzgruber","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022102614281373200_ehab642-B43","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ndt\/gfv009","article-title":"Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis","volume":"30","author":"Masson","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2022102614281373200_ehab642-B44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B45","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","article-title":"Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14779072.2019.1550718","article-title":"Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation?","volume":"17","author":"Romero","year":"2019","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2022102614281373200_ehab642-B47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/echo.12169","article-title":"B-type natriuretic peptide predicts left atrial appendage thrombus in patients with nonvalvular atrial fibrillation","volume":"30","author":"Doukky","year":"2013","journal-title":"Echocardiography"},{"key":"2022102614281373200_ehab642-B48","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.amjmed.2020.03.019","article-title":"Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial","volume":"133","author":"Guo","year":"2020","journal-title":"Am J Med"},{"key":"2022102614281373200_ehab642-B49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1378\/chest.14-2947","article-title":"Meta-analysis of randomized controlled trials of genotype-guided vs standard dosing of warfarin","volume":"148","author":"Dahal","year":"2015","journal-title":"Chest"},{"key":"2022102614281373200_ehab642-B50","first-page":"CD003839","article-title":"Self-monitoring and self-management of oral anticoagulation","volume":"7","author":"Heneghan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2022102614281373200_ehab642-B51","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B52","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B53","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/14017431.2019.1594353","article-title":"Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis","volume":"53","author":"Antza","year":"2019","journal-title":"Scand Cardiovasc J"},{"key":"2022102614281373200_ehab642-B55","doi-asserted-by":"crossref","first-page":"e2421","DOI":"10.1212\/WNL.0000000000007534","article-title":"Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"92","author":"Malhotra","year":"2019","journal-title":"Neurology"},{"key":"2022102614281373200_ehab642-B56","doi-asserted-by":"crossref","first-page":"e16194","DOI":"10.1097\/MD.0000000000016194","article-title":"Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: protocol for a systematic review and meta-analysis","volume":"98","author":"Shen","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2022102614281373200_ehab642-B57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann Intern Med"},{"key":"2022102614281373200_ehab642-B58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/AOG.0000000000002702","article-title":"Connect the dots\u2014July 2018","volume":"132","author":"Martimucci","year":"2018","journal-title":"Obstet Gynecol"},{"key":"2022102614281373200_ehab642-B59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-018-0501-y","article-title":"Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure","volume":"44","author":"Padrini","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2022102614281373200_ehab642-B60","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B61","first-page":"1319","article-title":"Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial fibrillation","volume":"22","author":"Brown","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2022102614281373200_ehab642-B62","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA"},{"key":"2022102614281373200_ehab642-B63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B64","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/1747493019895654","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany\u2014updated series of 120 cases","volume":"15","author":"Kermer","year":"2020","journal-title":"Int J Stroke"},{"key":"2022102614281373200_ehab642-B65","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B66","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.acvd.2019.02.003","article-title":"Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: the PAROS cross-sectional study of routine clinical practice","volume":"112","author":"Falissard","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"2022102614281373200_ehab642-B67","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B68","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2174\/092986712800167392","article-title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds","volume":"19","author":"Palmeira","year":"2012","journal-title":"Curr Med Chem"},{"key":"2022102614281373200_ehab642-B69","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.12659\/MSM.915875","article-title":"Long-term persistence with newly-initiated warfarin or non-VKA oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation: insights from the prospective China-AF registry","volume":"25","author":"Liu","year":"2019","journal-title":"Med Sci Monit"},{"key":"2022102614281373200_ehab642-B70","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/HJH.0000000000001228","article-title":"New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: an appraisal","volume":"35","author":"Borghi","year":"2017","journal-title":"J Hypertens"},{"key":"2022102614281373200_ehab642-B71","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/eurheartj\/ehu048","article-title":"Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial","volume":"35","author":"Coppens","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B72","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"Whitlock","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B74","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"2022102614281373200_ehab642-B75","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1093\/eurheartj\/ehv730","article-title":"Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry","volume":"37","author":"Boersma","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B76","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B77","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B78","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIRCULATIONAHA.108.844779","article-title":"Left atrial appendage occlusion does not eliminate the need for warfarin","volume":"120","author":"Whitlock","year":"2009","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B79","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1753944717711139","article-title":"Challenges in management of left ventricular thrombus","volume":"11","author":"Habash","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2022102614281373200_ehab642-B80","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacc.2017.12.031","article-title":"Left ventricular noncompaction: from physiologic remodeling to noncompaction cardiomyopathy","volume":"71","author":"Oechslin","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B81","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0002-9149(00)00780-3","article-title":"Relation between left ventricular and\/or left atrial thrombus and anticardiolipin antibodies in patients with acute myocardial infarction","volume":"85","author":"Guler","year":"2000","journal-title":"Am J Cardiol"},{"key":"2022102614281373200_ehab642-B82","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0002-9149(89)90878-3","article-title":"Diagnosis of left ventricular thrombi by magnetic resonance imaging and comparison with angiocardiography, computed tomography and echocardiography","volume":"64","author":"Sechtem","year":"1989","journal-title":"Am J Cardiol"},{"key":"2022102614281373200_ehab642-B83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B84","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022102614281373200_ehab642-B85","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B86","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B87","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2018.12.047","article-title":"Outcomes of direct oral anticoagulants in patients with mitral stenosis","volume":"73","author":"Kim","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B88","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehi667","article-title":"Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial","volume":"27","author":"P\u00e9rez-G\u00f3mez","year":"2006","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B89","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B90","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1161\/CIRCINTERVENTIONS.112.000124","article-title":"Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation","volume":"6","author":"Stortecky","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102614281373200_ehab642-B91","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1093\/eurheartj\/ehx390","article-title":"Thrombo-embolic prevention after transcatheter aortic valve implantation","volume":"38","author":"Vranckx","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B92","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B93","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B94","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/eurheartj\/ehx031","article-title":"Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke","volume":"38","author":"Vollema","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B95","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/eurheartj\/ehx369","article-title":"Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves","volume":"38","author":"Sondergaard","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B96","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B97","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1509233","article-title":"Possible subclinical leaflet thrombosis in bioprosthetic aortic valves","volume":"373","author":"Makkar","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B98","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B99","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2016.10.017","article-title":"Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study","volume":"184","author":"Windecker","year":"2017","journal-title":"Am Heart J"},{"key":"2022102614281373200_ehab642-B100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2018.03.008","article-title":"Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial","volume":"200","author":"Collet","year":"2018","journal-title":"Am Heart J"},{"key":"2022102614281373200_ehab642-B101","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa022831","article-title":"Acquired von Willebrand syndrome in aortic stenosis","volume":"349","author":"Vincentelli","year":"2003","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B102","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.thromres.2018.07.028","article-title":"Von Willebrand factor and the aortic valve: concepts that are important in the transcatheter aortic valve replacement era","volume":"170","author":"Ibrahim","year":"2018","journal-title":"Thromb Res"},{"key":"2022102614281373200_ehab642-B103","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B104","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B106","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B107","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"2022102614281373200_ehab642-B108","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B109","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B111","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B112","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B113","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B114","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B115","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2017.07.768","article-title":"Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54","volume":"70","author":"Bonaca","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B116","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B117","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B118","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B119","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B120","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(20)32236-4","article-title":"Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial","volume":"396","author":"Silvain","year":"2020","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B121","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehz453","article-title":"Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial","volume":"40","author":"Serruys","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B122","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B123","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B124","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jacc.2020.08.053","article-title":"Timing of oral P2Y12 inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome","volume":"76","author":"Tarantini","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B125","doi-asserted-by":"crossref","first-page":"e2018735","DOI":"10.1001\/jamanetworkopen.2020.18735","article-title":"Association of pretreatment With P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes","volume":"3","author":"Dworeck","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2022102614281373200_ehab642-B126","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.117.031062","article-title":"Frequency, predictors, and impact of combined antiplatelet therapy on venous thromboembolism in patients with symptomatic atherosclerosis","volume":"137","author":"Cavallari","year":"2018","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B127","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B128","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(20)32519-8","article-title":"Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets","volume":"397","author":"D'Ascenzo","year":"2021","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B129","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.0000158479.58589.0A","article-title":"Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein","volume":"111","author":"Maier","year":"2005","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/eurheartj\/ehm078","article-title":"Myeloid-related protein 8\/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes","volume":"28","author":"Altwegg","year":"2007","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B131","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/CIRCRESAHA.116.309692","article-title":"Neutrophil extracellular traps in atherosclerosis and atherothrombosis","volume":"120","author":"Doring","year":"2017","journal-title":"Circ Res"},{"key":"2022102614281373200_ehab642-B132","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurheartj\/ehy656","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","volume":"40","author":"Farag","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B133","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B134","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B135","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1161\/CIRCULATIONAHA.119.043613","article-title":"Very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial","volume":"140","author":"Watanabe","year":"2019","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B136","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B137","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaneurol.2019.2984","article-title":"Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial","volume":"77","author":"Perera","year":"2020","journal-title":"JAMA Neurol"},{"key":"2022102614281373200_ehab642-B138","doi-asserted-by":"crossref","first-page":"e007811","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102614281373200_ehab642-B139","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"2022102614281373200_ehab642-B140","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B141","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B142","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B143","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B144","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B145","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B146","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(18)31990-1","article-title":"Aspirin for primary prevention of cardiovascular disease","volume":"392","author":"Capodanno","year":"2018","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B147","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B148","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B149","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2018.10.050","article-title":"Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes","volume":"275","author":"Weidmann","year":"2019","journal-title":"Int J Cardiol"},{"key":"2022102614281373200_ehab642-B150","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B151","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"Mahmoud","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B152","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0735-1097(02)01730-8","article-title":"Transcutaneous detection of aortic arch atheromas by suprasternal harmonic imaging","volume":"39","author":"Schwammenthal","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B153","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0735-1097(99)00604-X","article-title":"Atheromas of the thoracic aorta: clinical and therapeutic update","volume":"35","author":"Tunick","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B154","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0735-1097(95)00431-9","article-title":"Natural history of severe atheromatous disease of the thoracic aorta: a transesophageal echocardiographic study","volume":"27","author":"Montgomery","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B155","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/STROKEAHA.109.548313","article-title":"Atherosclerotic disease of the proximal aorta and the risk of vascular events in a population-based cohort: the Aortic Plaques and Risk of Ischemic Stroke (APRIS) study","volume":"40","author":"Russo","year":"2009","journal-title":"Stroke"},{"key":"2022102614281373200_ehab642-B156","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/ATVBAHA.107.153544","article-title":"Differential impact of age, sex, and hypertension on aortic atherosclerosis: the Framingham Heart Study","volume":"28","author":"Oyama","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102614281373200_ehab642-B157","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJM199412013312202","article-title":"Atherosclerotic disease of the aortic arch and the risk of ischemic stroke","volume":"331","author":"Amarenco","year":"1994","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B158","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11886-012-0261-2","article-title":"Aortic atherosclerosis and embolic events","volume":"14","author":"Saric","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"2022102614281373200_ehab642-B159","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jacc.2004.05.075","article-title":"Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A prospective population-based transesophageal echocardiography study","volume":"44","author":"Meissner","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B160","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jacc.2008.04.062","article-title":"Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study","volume":"52","author":"Di Tullio","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B161","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.jacc.2011.08.023","article-title":"2011 ACCF\/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"58","author":"Rooke","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B162","doi-asserted-by":"crossref","first-page":"e669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"},{"key":"2022102614281373200_ehab642-B163","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B164","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0002-9149(02)02870-9","article-title":"Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque","volume":"90","author":"Tunick","year":"2002","journal-title":"Am J Cardiol"},{"key":"2022102614281373200_ehab642-B165","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/CIRCULATIONAHA.108.811935","article-title":"Aortic arch plaques and risk of recurrent stroke and death","volume":"119","author":"Di Tullio","year":"2009","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B166","first-page":"CD010453","article-title":"Aspirin as adjunctive treatment for giant cell arteritis","volume":"8","author":"Mollan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2022102614281373200_ehab642-B167","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","article-title":"Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022102614281373200_ehab642-B168","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","article-title":"Antiplatelet and anticoagulant therapy in patients with giant cell arteritis","volume":"54","author":"Lee","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022102614281373200_ehab642-B169","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7861\/clinmedicine.10-4-381","article-title":"Concise guidance: diagnosis and management of giant cell arteritis","volume":"10","author":"Dasgupta","year":"2010","journal-title":"Clin Med (Lond)"},{"key":"2022102614281373200_ehab642-B170","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.CIR.0000145170.22652.51","article-title":"Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy","volume":"110","author":"Lima","year":"2004","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B171","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1093\/eurheartj\/ehu281","article-title":"2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC)","volume":"35","author":"Erbel","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B172","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO). The Task Force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B173","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(08)60691-1","article-title":"Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis","volume":"371","author":"Pickett","year":"2008","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B174","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00270-005-5288-y","article-title":"Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting","volume":"29","author":"Dalainas","year":"2006","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2022102614281373200_ehab642-B176","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejvs.2005.01.012","article-title":"The benefits of combined anti-platelet treatment in carotid artery stenting","volume":"29","author":"McKevitt","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2022102614281373200_ehab642-B177","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B178","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.CIR.0000163561.90680.1C","article-title":"Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial","volume":"111","author":"Markus","year":"2005","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B179","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1161\/01.STR.0000260187.33864.a7","article-title":"Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and multi MERCI part I trials","volume":"38","author":"Flint","year":"2007","journal-title":"Stroke"},{"key":"2022102614281373200_ehab642-B180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"2022102614281373200_ehab642-B181","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0140-6736(19)31721-0","article-title":"An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction","volume":"394","author":"Attia","year":"2019","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B182","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B183","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1105335","article-title":"Stenting versus aggressive medical therapy for intracranial arterial stenosis","volume":"365","author":"Chimowitz","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B184","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMoa1802712","article-title":"Five-year risk of stroke after TIA or minor ischemic stroke","volume":"378","author":"Amarenco","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B185","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B186","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B187","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B188","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B189","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B190","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/ene.12982","article-title":"Dual antiplatelet therapy after stroke or transient ischaemic attack\u2014how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis","volume":"23","author":"Ge","year":"2016","journal-title":"Eur J Neurol"},{"key":"2022102614281373200_ehab642-B191","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1067\/mva.2002.126087","article-title":"Effect of intraluminal thrombus on wall stress in patient-specific models of abdominal aortic aneurysm","volume":"36","author":"Wang","year":"2002","journal-title":"J Vasc Surg"},{"key":"2022102614281373200_ehab642-B192","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/bjs.8707","article-title":"Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms","volume":"99","author":"Sweeting","year":"2012","journal-title":"Br J Surg"},{"key":"2022102614281373200_ehab642-B193","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jvs.2016.04.061","article-title":"Low-dose aspirin and rupture of abdominal aortic aneurysm","volume":"65","author":"Wemmelund","year":"2017","journal-title":"J Vasc Surg"},{"key":"2022102614281373200_ehab642-B194","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1161\/CIRCULATIONAHA.109.886465","article-title":"Cholesterol embolization syndrome","volume":"122","author":"Kronzon","year":"2010","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jvs.2010.02.012","article-title":"An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance","volume":"52","author":"Thompson","year":"2010","journal-title":"J Vasc Surg"},{"key":"2022102614281373200_ehab642-B196","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jvs.2015.01.032","article-title":"Clinical outcome and morphologic determinants of mural thrombus in abdominal aortic endografts","volume":"61","author":"Oliveira","year":"2015","journal-title":"J Vasc Surg"},{"key":"2022102614281373200_ehab642-B197","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/eurheartj\/eht492","article-title":"Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF","volume":"35","author":"Jones","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B198","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jvs.2010.02.290","article-title":"The effect of warfarin therapy on endoleak development after endovascular aneurysm repair (EVAR) of the abdominal aorta","volume":"52","author":"Bobadilla","year":"2010","journal-title":"J Vasc Surg"},{"key":"2022102614281373200_ehab642-B199","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1583\/13-4462R.1","article-title":"Impact of long-term warfarin treatment on EVAR durability: a meta-analysis","volume":"21","author":"Lazarides","year":"2014","journal-title":"J Endovasc Ther"},{"key":"2022102614281373200_ehab642-B200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2017.06.015","article-title":"Generation and characterization of aptamers targeting factor XIa","volume":"156","author":"Woodruff","year":"2017","journal-title":"Thromb Res"},{"key":"2022102614281373200_ehab642-B201","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11936-017-0523-9","article-title":"Acute aortic syndromes: update in current medical management","volume":"19","author":"Morris","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2022102614281373200_ehab642-B202","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2010.09.011","article-title":"Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery","volume":"41(Suppl 1)","author":"Moll","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2022102614281373200_ehab642-B203","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"2022102614281373200_ehab642-B204","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM199202063260605","article-title":"Mortality over a period of 10 years in patients with peripheral arterial disease","volume":"326","author":"Criqui","year":"1992","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B206","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.2018.5422","article-title":"Antithrombotic therapy for peripheral artery disease in 2018","volume":"319","author":"Hess","year":"2018","journal-title":"JAMA"},{"key":"2022102614281373200_ehab642-B207","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1093\/eurheartj\/ehy649","article-title":"European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism","volume":"40","author":"Pristipino","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B208","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"key":"2022102614281373200_ehab642-B209","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"2022102614281373200_ehab642-B210","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B211","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B212","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2\u00b0P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B213","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2008","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B214","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"2022102614281373200_ehab642-B215","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1161\/CIRCULATIONAHA.117.024469","article-title":"A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) initiative","volume":"135","author":"Hess","year":"2017","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B216","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102614281373200_ehab642-B217","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B218","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1067\/mva.2002.121847","article-title":"Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study","volume":"35","author":"Johnson","year":"2002","journal-title":"J Vasc Surg"},{"key":"2022102614281373200_ehab642-B219","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B220","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B221","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"2022102614281373200_ehab642-B222","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1093\/eurheartj\/ehx003","article-title":"Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function","volume":"39","author":"Mazzolai","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B223","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B224","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"key":"2022102614281373200_ehab642-B225","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B226","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2022102614281373200_ehab642-B227","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B228","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B229","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","article-title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","volume":"370","author":"Meyer","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B230","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2011.04388.x","article-title":"Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study","volume":"9","author":"Zondag","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2022102614281373200_ehab642-B231","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(11)60824-6","article-title":"Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial","volume":"378","author":"Aujesky","year":"2011","journal-title":"Lancet"},{"key":"2022102614281373200_ehab642-B232","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archinternmed.2010.199","article-title":"Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism","volume":"170","author":"Jimenez","year":"2010","journal-title":"Arch Intern Med"},{"key":"2022102614281373200_ehab642-B233","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/eurheartj\/ehy873","article-title":"Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis","volume":"40","author":"Barco","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B234","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/eurheartj\/ehz367","article-title":"Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor xa inhibitor rivaroxaban. An International Multicentre Single-arm Clinical Trial","volume":"41","author":"Barco","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102614281373200_ehab642-B235","doi-asserted-by":"crossref","first-page":"d3036","DOI":"10.1136\/bmj.d3036","article-title":"Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials","volume":"342","author":"Boutitie","year":"2011","journal-title":"BMJ"},{"key":"2022102614281373200_ehab642-B236","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102614281373200_ehab642-B237","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.14017","article-title":"Use of direct oral anticoagulants in antiphospholipid syndrome","volume":"16","author":"Cohen","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2022102614281373200_ehab642-B238","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022102614281373200_ehab642-B239","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/10\/940\/46645178\/ehab642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/10\/940\/46645178\/ehab642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T20:57:50Z","timestamp":1673211470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/10\/940\/6384672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":239,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,8]]},"published-print":{"date-parts":[[2022,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab642","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,7]]},"published":{"date-parts":[[2021,10,8]]}}}